Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now full pipeline small index

Bacterial Vaginosis: full-pipeline trial registry

3 of 16 indexed Bacterial Vaginosis trials are currently recruiting.

Corpus placement: #1,060 of 28,707 conditions by registered trial count.

16 US clinical trials · 3 currently recruiting · #1,060 of 28,707 conditions by registered trial count

Bacterial Vaginosis: 16 US clinical trials tracked, 3 recruiting.

Bacterial Vaginosis is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 3 of these trials.

Enrollment posture brief

Registry condition bacterial-vaginosis

OPEN 3 | RECR 19% | LATE 5 | EARLY 5 | RANK #1060 | SPON 3

Nearest open-share peer: Myelodysplastic/Myeloproliferative Neoplasms (19% recruiting · 16 trials)

Adolescent62.5%Alcohol Intoxication56.3%AL Amyloidosis43.8%Bacterial Vaginosis (this)19%Allergy18.8%
Open-enrollment share among volume-matched conditions near Bacterial Vaginosis

Bacterial Vaginosis lists 3 open slots (19% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Bacterial Vaginosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Bacterial Vaginosis is recruiting below its size-band peers.

    3 of 16 indexed trials (18.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Bacterial Vaginosis research.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 3 of 16 trials (18.8%). 13 distinct sponsors appear on at least one study for this condition label.

  3. Typical Bacterial Vaginosis enrolment sits around 234 participants.

    Median target enrolment is 234 among the 16 trials that report a genuine target (sentinel values excluded). 6 of those (37.5%) plan for fewer than 100 participants.

  4. Bacterial Vaginosis research is mostly interventional.

    13 interventional and 3 observational studies make up this index (81.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 24Phase 32Phase 43

Open and recent trials

16 total, page 1 of 1

RECRUITING 550 participants

Prospective Data Bank Creation to Study Vaginal Conditions

Texas Tech University Health Sciences Center

NCT01829204

RECRUITING Early Phase 1 22 participants

Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome

Queen's Medical Center

NCT05753813

RECRUITING NA 9 participants

Clinical Protocol CERN Feasibility Study

Cern Corporation

NCT06933420

ACTIVE NOT RECRUITING Phase 2 408 participants

Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs

Rush University Medical Center

NCT05666778

COMPLETED Phase 3 871 participants

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

Balmoral Medical company

NCT03091777

COMPLETED 738 participants

Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis

Hoffmann-La Roche

NCT06975436

COMPLETED Phase 3 604 participants

A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women

Actavis

NCT02210689

COMPLETED Phase 4 593 participants

Treatment of Bacterial Vaginosis (BV) With Tinidazole

University of Alabama at Birmingham

NCT00334633

COMPLETED 519 participants

A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test

University of Pittsburgh

NCT00682851

COMPLETED Phase 2 234 participants

Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01230814

COMPLETED Phase 2 228 participants

LACTIN-V Study for Recurrent Bacterial Vaginosis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02766023

COMPLETED NA 118 participants

Vitamin D and Sexual Health

Ohio State University

NCT01450462

COMPLETED Phase 4 81 participants

Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity

University of Washington

NCT02432404

COMPLETED Phase 2 81 participants

Suppression Of Bacterial Vaginosis (BV) [SUBVert]

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03930745

COMPLETED Phase 4 12 participants

Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study

University of Pittsburgh

NCT00464542

COMPLETED NA 6 participants

Flourish HEC to Prevent Recurrence of BV

Vaginal Biome Science

NCT05386147

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 2
Phase 4 3

Named interventions

Most-linked intervention names on Bacterial Vaginosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Metronidazole Drug
2 trials
Placebo Other
2 trials
Placebo Drug
2 trials
Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components) Device
1 trials
Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate) Drug
1 trials
TOL-463 Drug
1 trials
Metronidazole Vaginal Gel 0.75% Drug
1 trials
GDC-229 Drug
1 trials

US sites by state

Facility locations filed on Bacterial Vaginosis trials. A trial with sites in several states counts in each.

Pennsylvania 5 trials
California 5 trials
Alabama 4 trials
Texas 3 trials
Illinois 3 trials
North Carolina 2 trials
Missouri 2 trials
Florida 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Bacterial Vaginosis page

16 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bacterial Vaginosis condition card totals 16 registered trials; most-linked intervention Metronidazole; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.